Al-Razi Medical Company (9572) fair value: what the stock is really worth
We calculate from audited financials what Al-Razi Medical Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Al-Razi Medical Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
39‑month range 25.10 SAR – 81.70 SAR · fair‑value band 8.90 SAR – 15.32 SAR · the 25.48 SAR price screens above the 11.86 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Al-Razi Medical Company engages in the retail sale of medical devices, equipment, and supplies in the Kingdom of Saudi Arabia. The company is involved in the operation of medical device, cosmetic, and pharmaceutical warehouses; specialized and general medical complexes; and one-day surgery centers.
Show more
Al-Razi Medical Company engages in the retail sale of medical devices, equipment, and supplies in the Kingdom of Saudi Arabia. The company is involved in the operation of medical device, cosmetic, and pharmaceutical warehouses; specialized and general medical complexes; and one-day surgery centers. It also engages in the land transport of goods; operation of storage facilities; and provision of shipping and distribution services. The company was founded in 1986 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.
Stock analysis
Al-Razi Medical Company (9572) currently trades at 25.48 SAR, while our model-based Fair Value estimate is 11.86 SAR, implying the stock looks roughly 114.8% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 26.67 SAR per share, and 8 of the 24 models we run sit above the 25.48 SAR price.
Bear case: the Economic Profit group reads lowest at 5.96 SAR, and 16 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: 8.90 SAR (bear) to 15.32 SAR (bull), the price of 25.48 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Al-Razi Medical Company reported revenue of 74.4M SAR in FY2025 versus 45.2M SAR in FY2021, a compound +13.3%/yr. Reported net income was 819K SAR in FY2025, compounding −21.5%/yr from FY2021.
Key figures
Market cap 42.4M SAR (≈ $11.3M) · P/E ratio 47.2 · P/S ratio 0.52 · EPS (TTM) 0.5400 SAR · Net margin 1.1% · Return on equity 3.6% · Return on assets (EBIT) 4.3% · Operating margin 2.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −53%, 9572 screens richer than that median.
Fair Value models
Bear 8.90 SARFair Value 11.86 SARBull 15.32 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.3817 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.6%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 2%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.7%
Yearly growth needed for the next five years to justify today's price.
Compare Al-Razi Medical Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 58 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−54% · Bottom 25%
Profitability
Return on equity (TTM)4% · Below median
Return on assets2% · Above median
Net margin (TTM)1% · Below median
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth34% · Top 25%
Balance sheet
Debt / equity0.04× · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)47.2× · Priciest 25%
P/B0.48× · Cheapest 25%
P/S (TTM)0.15× · Cheaper than median
P/FCF2.9× · Priciest 25%
EV/EBITDA3.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 29
FUTURE (revenue growth)100· sector 21
PAST (return on equity)14· sector 15
HEALTH (low debt)98· sector 98
DIVIDEND (yield)0· sector 66
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Al-Razi Medical Company Fair Value". https://www.fairvalue-calculator.com/stock/9572
Frequently asked questions
Is Al-Razi Medical Company (9572) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 11.86 SAR versus a price of 25.48 SAR, about −53% upside (overvalued).
What is the fair value of 9572?
Our model-based fair value for Al-Razi Medical Company is 11.86 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 25.48 SAR.
What is the quality score of 9572?
Al-Razi Medical Company has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Al-Razi Medical Company (9572)?
Our model-based price target is the fair value of 11.86 SAR (as of Sep 13, 2026) from 24 valuation models. Cautious scenario 8.90 SAR, optimistic scenario 15.32 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Al-Razi Medical Company stock forecast for 2026?
Our models put fair value at 11.86 SAR, about −53% upside versus a price of 25.48 SAR (overvalued). Cautious scenario 8.90 SAR, optimistic scenario 15.32 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Al-Razi Medical Company (9572)?
Al-Razi Medical Company reported trailing-twelve-month revenue of about 74.4M SAR (latest available figure, as of Sep 13, 2026).
What growth is priced into Al-Razi Medical Company (9572)?
For today's price to be fair in a discounted-cash-flow model, Al-Razi Medical Company would have to grow free cash flow by -3.7 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +13.3 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of 9572 use?
Our models discount Al-Razi Medical Company at 9.0 %: a base by market capitalisation (nano), damped by beta 0.31, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Al-Razi Medical Company that is -3.7 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Al-Razi Medical Company (9572) delivered so far?
Over the past 4 years revenue at Al-Razi Medical Company grew +13.3 % a year. The price currently implies -3.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Al-Razi Medical Company (9572) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Al-Razi Medical Company (-3.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Al-Razi Medical Company (9572)?
The free-cash-flow yield on the price is 9.94 %: that much free cash flow Al-Razi Medical Company produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Al-Razi Medical Company (9572)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Al-Razi Medical Company it is 11.86 SAR per share (as of Sep 13, 2026), against a price of 25.48 SAR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Al-Razi Medical Company stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9572 trades above its calculated fair value: price 25.48 SAR, fair value 11.86 SAR, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9572?
No. The price is what the market pays today (25.48 SAR); the fair value is what the company's own numbers justify (11.86 SAR). For Al-Razi Medical Company the two are 13.62 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Al-Razi Medical Company worth?
The market values Al-Razi Medical Company at about 42.4M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 25.48 SAR; our models calculate a fair value of 11.86 SAR per share.
What do the bullish and bearish scenarios say about 9572?
Our models span a range for Al-Razi Medical Company: cautious scenario 8.90 SAR, base 11.86 SAR, optimistic 15.32 SAR per share (as of Sep 13, 2026, price 25.48 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9572?
Al-Razi Medical Company trades at a price-to-earnings ratio of 47.2 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 11.86 SAR is built from several models across several years. Other multiples: P/B 0.5, P/S 0.2, EV/EBITDA 3.7.
How solid is the balance sheet of Al-Razi Medical Company (9572)?
Balance-sheet figures for Al-Razi Medical Company (as of Sep 13, 2026): return on equity 3.6%, debt of 0.04 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 9572 from its 52-week high?
Al-Razi Medical Company trades at 25.48 SAR, about 39% below its 52-week high of 41.96 SAR and 2% above the low of 25.10 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 11.86 SAR is for.
Which stocks are comparable to Al-Razi Medical Company?
From the same area (Healthcare) we also value JD Health International Inc, Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Al-Razi Medical Company stock attractive at the current price?
The data as of Sep 13, 2026: price 25.48 SAR, calculated fair value 11.86 SAR (−53%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9572 calculated?
We run Al-Razi Medical Company through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11.86 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Al-Razi Medical Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Al-Razi Medical Company (9572)?
The closing price on Sep 13, 2026 was 25.48 SAR. Our model-based fair value is 11.86 SAR, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Al-Razi Medical Company right now?
The price sits above even our optimistic bull case (15.32 SAR). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Al-Razi Medical Company
How large is the market capitalisation of Al-Razi Medical Company (9572)?
The market capitalisation of Al-Razi Medical Company is 42.4M SAR (≈ $11.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Al-Razi Medical Company (9572)?
The price-to-sales ratio of Al-Razi Medical Company is 0.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Al-Razi Medical Company (9572)?
Earnings per share at Al-Razi Medical Company are 0.5400 SAR (price ÷ EPS = P/E 47.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Al-Razi Medical Company (9572)?
The net margin of Al-Razi Medical Company is 1.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Al-Razi Medical Company (9572)?
The return on equity (ROE) of Al-Razi Medical Company is 3.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Al-Razi Medical Company (9572)?
On an EBIT basis the return on assets of Al-Razi Medical Company is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Al-Razi Medical Company (9572)?
The operating margin of Al-Razi Medical Company is 2.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Al-Razi Medical Company (9572)?
Revenue at Al-Razi Medical Company is growing +34.0% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Al-Razi Medical Company (9572)?
Earnings per share at Al-Razi Medical Company are growing +325% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Al-Razi Medical Company (9572) carry?
The net debt of Al-Razi Medical Company is 2.5M SAR (fiscal year 2025, ≈ 0.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Al-Razi Medical Company in the live analysis
One click puts Al-Razi Medical Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
